University of Bath and Qualasept Limited
Lead Participant:
UNIVERSITY OF BATH
Abstract
To develop, validate and implement novel methods for the characterisation of drugs in this class under extended storage. New products will be produced that have extended shelf lives. Antibody based drugs that work by engaging T cells are an exciting new class of cancer therapy.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| UNIVERSITY OF BATH | £329,211 | £ 164,606 |
Participant |
||
| KTN LTD | ||
| THE UNIVERSITY OF BATH | ||
| QUALASEPT LIMITED |
People |
ORCID iD |